Fluconazole

also known as Diflucan · UK-49,858 · FCZ · FLZ · [3H]-Fluconazole · Alkanazole · BAYT-006267 · Canesten oral · +9 more

Small molecule targets CYP2C19, CYP2C9, CYP3A4 via inhibition

Developed for: HIV infectious disease · Cryptococcal meningitis · candidiasis · fungal infectious disease · oral candidiasis · Crohn disease · esophageal candidiasis · neoplasm
+33 more
· aspergillosis · coccidioidomycosis · histoplasmosis · sporotrichosis · vulvovaginal candidiasis · AIDS dementia complex · autism spectrum disorder · bacterial vaginosis · blastomycosis · candidemia · candidiasis, invasive · cutaneous leishmaniasis · dermatophytosis of scalp or beard · diabetes mellitus · fungal keratitis · fungal lung infectious disease · idiopathic hypercalciuria · infectious disease · intestinal perforation · meningitis · mouth disorder · peptic ulcer perforation · pityriasis versicolor · sexually transmitted disease · tinea unguium · urinary bladder disorder · vaginal discharge · vaginitis · autoinflammatory syndrome · cryptococcosis · infectious disease with sepsis · paronychia · tinea corporis
Investigated by: Pfizer · National Institute of Allergy and Infectious Diseases (NIAID) · Eli Lilly and Company · Jiangsu HengRui Medicine Co., Ltd. · Boehringer Ingelheim · National Heart, Lung, and Blood Institute (NHLBI)
+127 more
· ANRS, Emerging Infectious Diseases · Alexion Pharmaceuticals, Inc. · Assiut University · Children's Hospital of Philadelphia · Daniel Benjamin · Enanta Pharmaceuticals, Inc · F2G Ltd · Millennium Pharmaceuticals, Inc. · National Cancer Institute (NCI) · Rigshospitalet, Denmark · Schering-Plough · University of Alabama at Birmingham · University of Minnesota · University of Pennsylvania · University of Sherbrooke · Washington University School of Medicine · Academic Medical Center - University of Amsterdam · Acerta Pharma BV · Agency for Healthcare Research and Quality (AHRQ) · Ahon Pharmaceutical Co., Ltd. · Altasciences Company Inc. · Astellas Pharma Global Development, Inc. · AstraZeneca · BeiGene · Blood and Marrow Transplant Clinical Trials Network · Bochud Pierre-Yves · Bristol-Myers Squibb · CHU Kamenge, BURUNDI · CSPC Ouyi Pharmaceutical Co., Ltd. · CTI BioPharma · Canadian International Development Agency · Capital Medical University · Celerion · Celgene Corporation · Centers for Disease Control and Prevention · Concert Pharmaceuticals · Conselho Nacional de Desenvolvimento Científico e Tecnológico · Crohn's and Colitis Foundation · DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Dalhousie University · Department for International Development, United Kingdom · Dr. Frank Arguello Cancer Clinic · Eisai Inc. · Emory University · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Federal University of Bahia · Food and Drug Administration (FDA) · Fred Hutchinson Cancer Center · French National Institute of Health and Medical Research · Genentech, Inc. · GlaxoSmithKline · Hadassah Medical Organization · Hospices Civils de Lyon · Hospital Avicenne · Hospital Universitário Professor Edgard Santos · Hunan Cancer Hospital · Hutchmed · Hôpital Cocody · Hôpital de Treichville · Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation · Indian Council of Medical Research · Infectious Diseases Institute, Uganda · Institut Pasteur · Institut de Médecine et Epidémiologie Appliquée (IMEA) · Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia.com · Janssen Pharmaceuticals · Janssen Research & Development, LLC · Jazz Pharmaceuticals · Jemincare · Johns Hopkins University · Khyber Teaching Hospital · Klinik für Hämatologie, Aachen · Kowa Research Institute, Inc. · Makerere University · all 133 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (2)	US (FDA)	DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER	—	1993-12-30 – 1994-11-23	fda.gov ↗
Approved	US (FDA)	DIFLUCAN	—	1990-01-29	fda.gov ↗

Trials 139 · started per year

today

US approved 1990

1989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 03 trials
Phase 0	NCT07295314	Jan 2026 → Oct 2027 expected	fungal infectious disease	Academic Medical Center - University of Amsterdam	Not yet recruiting	No outcome recorded
Phase 0	NCT04502277	Sep → Dec 2020	candidiasis	Sutphin Drugs	Unknown	No outcome recorded
Phase 0	NCT00503542	Feb 2007 → Feb 2008	vaginitis	Agency for Healthcare Research and Quality (AHRQ)	Completed	No outcome recorded
Phase 148 trials
Phase 1	NCT07565441	May → Nov 2026 expected	autosomal dominant polycystic kidney disease	Jemincare	Not yet recruiting	No outcome recorded
Phase 1	NCT07439250	Mar → Apr 2026	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT07395024	Feb → Jul 2026 overdue	—	Astellas Pharma Global Development, Inc.	Recruiting	No outcome recorded
Phase 1	NCT07636018	Aug → Oct 2025	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT06593457	Aug → Oct 2024	—	Nurix Therapeutics, Inc.	Completed	No outcome recorded
Phase 1	NCT06345794	Apr → Jun 2024	—	DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT06173596	Jan → Apr 2024	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT06822166	Dec 2023 → Jan 2024	—	Ahon Pharmaceutical Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT05661591	Feb → Mar 2023	cancer	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT05657613	Jan → Jun 2023	—	CTI BioPharma	Completed	No outcome recorded
Phase 1	NCT05478772	Jul → Aug 2022	—	Concert Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT05602597	Jun → Aug 2022	lymphoma	Hutchmed	Completed	No outcome recorded
Phase 1	NCT05147727	Mar → May 2022	neoplasm	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT04933682	Jun → Aug 2021	—	Alexion Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT04850651	Apr → May 2021	—	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT04464577	Apr → Jun 2021	—	Bristol-Myers Squibb	Withdrawn	No outcome recorded
Phase 1	NCT04871724	Mar 2021	respiratory syncytial virus infectious disease	Enanta Pharmaceuticals, Inc	Completed	No outcome recorded
Phase 1	NCT04702464	Jan → May 2021	—	Celgene Corporation	Completed	No outcome recorded
Phase 1	NCT04551963	Nov 2020 → Feb 2022	B-cell neoplasm	BeiGene	Completed	No outcome recorded
Phase 1	NCT05140096	Jan → Apr 2020	—	Acerta Pharma BV	Completed	No outcome recorded
Phase 1	NCT04038008	Jul → Sep 2019	—	Pharmtechnology LLC	Completed	No outcome recorded
Phase 1	NCT04193319	Jul → Sep 2019	—	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT03942029	Jun → Dec 2019	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT04201054	Mar → Apr 2019	—	Parc de Salut Mar	Completed	No outcome recorded
Phase 1	NCT03634345	Sep → Dec 2018	atopic eczema	Pfizer	Completed	No outcome recorded
Phase 1	NCT03610945	Jul → Aug 2018	metabolic dysfunction-associated steatohepatitis	Enanta Pharmaceuticals, Inc	Completed	No outcome recorded
Phase 1	NCT03451110	Feb → Mar 2018	—	Eisai Inc.	Completed	No outcome recorded
Phase 1	NCT03135106	Apr → Sep 2017	—	Janssen Research & Development, LLC	Completed	No outcome recorded
Phase 1	NCT02730442	Feb → Jun 2016	invasive aspergillosis	F2G Ltd	Completed	No outcome recorded
Phase 1	NCT02325011	Nov 2014 → Feb 2015	—	Jazz Pharmaceuticals	Completed	No outcome recorded
Phase 1	NCT02222922	Oct 2014 → Nov 2019	neoplasm	Pfizer	Completed	No outcome recorded
Phase 1	NCT02275975	Jul → Aug 2014	—	Kowa Research Institute, Inc.	Completed	No outcome recorded
Phase 1	NCT02122770	Apr 2014 → Jun 2017	—	Millennium Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT02093728	Apr → Jun 2014	cancer	AstraZeneca	Completed	No outcome recorded
Phase 1	NCT02093390	Mar → Apr 2014	endometriosis, prostate cancer	Millennium Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT01950507	Feb 2014 → May 2018	graft versus host disease	National Institutes of Health Clinical Center (CC)	Terminated	No outcome recorded
Phase 1	NCT01924299	Aug → Nov 2013	—	Eli Lilly and Company	Completed	No outcome recorded
Phase 1	NCT01772290	Feb → May 2013	—	Genentech, Inc.	Completed	No outcome recorded
Phase 1	NCT01386593	May 2011 → Jan 2012	—	University Hospital, Basel, Switzerland	Completed	No outcome recorded
Phase 1	NCT01169402	Jul 2010 → Feb 2013	cardiac arrest, fungal infectious disease	Michael Cohen-Wolkowiez	Completed	No outcome recorded
Phase 1	NCT01153724	May → Jul 2010	chronic obstructive pulmonary disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00935363	Feb → Mar 2010	—	University of California, San Francisco	Withdrawn	No outcome recorded
Phase 1	NCT00964106	Aug 2009 → Aug 2011	—	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00911235	May → Jul 2009	overactive bladder	Pfizer	Completed	No outcome recorded
Phase 1	NCT00797420	Nov 2008 → Jan 2010	candidiasis	Daniel Benjamin	Completed	No outcome recorded
Phase 1	NCT02195466	Jun → Jul 2003	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00000788	? → Jun 1994	HIV infectious disease, candidiasis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00000826	? → May 1999	HIV infectious disease, bacterial infectious disease, fungal infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 1/24 trials
Phase 1/2	NCT03036046	Mar → Sep 2017	acute myeloid leukemia	F2G Ltd	Withdrawn	No outcome recorded
Phase 1/2	NCT01354314	Nov 2010 → Mar 2016	AIDS dementia complex	Johns Hopkins University	Completed	No outcome recorded
Phase 1/2	NCT00885703	Apr 2010 → Jan 2017	Cryptococcal meningitis, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/2	NCT01026714	Nov 2009 → Aug 2010	—	University Hospital, Geneva	Completed	No outcome recorded
Phase 213 trials
Phase 2	NCT04495608	Jan 2021 → Jul 2024	idiopathic hypercalciuria, nephrocalcinosis, nephrolithiasis	Hospices Civils de Lyon	Completed	No outcome recorded
Phase 2	NCT04273178	Jan 2020 → Jan 2022	fungal infectious disease	Shanghai Jiao Tong University School of Medicine	Unknown	No outcome recorded
Phase 2	NCT03476317	Jul 2018 → Dec 2020	Crohn disease	Children's Hospital of Philadelphia	Completed	No outcome recorded
Phase 2	NCT02765256	Aug 2016 → Dec 2018	Crohn disease	University of Pennsylvania	Completed	No outcome recorded
Phase 2	NCT01683760	Sep 2012 → Oct 2014	—	Seoul National University Hospital	Completed	No outcome recorded
Phase 2	NCT02941068	Mar 2012 → Jun 2016	intestinal perforation	Nanjing PLA General Hospital	Completed	No outcome recorded
Phase 2	NCT02366884	Jul 2011 → Dec 2022	neoplasm	Dr. Frank Arguello Cancer Clinic	Unknown	No outcome recorded
Phase 2	NCT02997059	Jul 2008 → Jun 2014	Crohn disease	University Hospital, Lille	Completed	No outcome recorded
Phase 2	NCT00145249	May 2005 → Apr 2008	Cryptococcal meningitis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00166166	Jul 2002 → Jan 2013	hyperlipidemia	Emory University	Terminated	No outcome recorded
Phase 2	NCT00004938	Aug 1996	sporotrichosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT00004808	Sep 1991 → ?	blastomycosis, histoplasmosis, sporotrichosis	National Center for Research Resources (NCRR)	Completed	No outcome recorded
Phase 2	NCT00002399	—	HIV infectious disease, oral candidiasis	Schering-Plough	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT02145832	Oct 2014 → Nov 2015	candidiasis	French National Institute of Health and Medical Research	Completed	No outcome recorded
Phase 2/3	NCT01715922	May 2012 → Sep 2015	Cryptococcal meningitis, HIV infectious disease	ANRS, Emerging Infectious Diseases	Unknown	No outcome recorded
Phase 2/3	NCT00002533	Feb 1993 → Jun 2006	head and neck cancer, infectious disease, mouth disorder	University of Miami	Completed	No outcome recorded
Phase 323 trials
Phase 3	NCT06274554	Oct 2024 → Dec 2028 expected	Crohn disease	Weill Medical College of Cornell University	Recruiting	No outcome recorded
Phase 3	NCT05848492	May → Oct 2021	candidiasis, invasive	Services Institute of Medical Sciences, Pakistan	Completed	No outcome recorded
Phase 3	NCT03171584	Jul 2017 → Jun 2019	—	Assiut University	Unknown	No outcome recorded
Phase 3	NCT01953744	Feb 2014 → Apr 2015	cutaneous leishmaniasis	Hospital Universitário Professor Edgard Santos	Terminated	No outcome recorded
Phase 3	NCT01825031	Jun 2013 → Mar 2016	HIV infectious disease	Medical Research Council	Completed	No outcome recorded
Phase 3	NCT01806623	Mar → Nov 2013	vulvovaginal candidiasis	Pfizer	Completed	No outcome recorded
Phase 3	NCT02111629	May 2012 → Feb 2013	vaginal discharge	National University of Colombia	Completed	No outcome recorded
Phase 3	NCT00734539	Nov 2008 → Dec 2011	candidiasis	Daniel Benjamin	Completed	No outcome recorded
Phase 3	NCT01524081	Jul 2008 → Jul 2011	appendicitis, intestinal obstruction, peptic ulcer perforation	The Faculty Hospital Na Bulovce	Completed	No outcome recorded
Phase 3	NCT00353561	Jun 2004 → Apr 2006	diabetes mellitus, vulvovaginal candidiasis	Indian Council of Medical Research	Completed	No outcome recorded
Phase 3	NCT00313131	Jan 2004 → May 2005	bacterial vaginosis, candidiasis	University of Sherbrooke	Completed	No outcome recorded
Phase 3	NCT00170430	May 2003 → Dec 2006	bacterial infectious disease, fungal infectious disease, sexually transmitted disease	University of Washington	Completed	No outcome recorded
Phase 3	NCT00056368	Mar 2003 → Oct 2004	candidiasis	Pfizer	Completed	No outcome recorded
Phase 3	NCT00645242	Nov 2002 → Mar 2003	dermatophytosis of scalp or beard	Pfizer	Completed	No outcome recorded
Phase 3	NCT00001937	Nov 1999 → Dec 2000	aspergillosis, candidiasis	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 3	NCT00003883	Oct 1998 → Jul 2002	cancer	Fred Hutchinson Cancer Center	Completed	No outcome recorded
Phase 3	NCT00163111	Sep 1998 → May 2003	candidemia	Pfizer	Completed	No outcome recorded
Phase 3	NCT00002446	Aug 1998 → ?	HIV infectious disease, oral candidiasis	Schering-Plough	Completed	No outcome recorded
Phase 3	NCT00002122	—	HIV infectious disease, Mycobacterium avium complex disease, fungal infectious disease	Pfizer	Completed	No outcome recorded
Phase 3	NCT00001017	? → Jul 1991	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
Phase 3	NCT00002339	—	HIV infectious disease, esophageal candidiasis	Pfizer	Completed	No outcome recorded
Phase 3	NCT00002277	—	HIV infectious disease, fungal infectious disease	Pfizer	Completed	No outcome recorded
Phase 3	NCT00000676	? → Nov 1993	HIV infectious disease, candidiasis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 412 trials
Phase 4	NCT06922344	Mar → Dec 2025 overdue	pityriasis versicolor	Khyber Teaching Hospital	Recruiting	No outcome recorded
Phase 4	NCT06709196	Jan 2025 → Jan 2027 expected	urinary bladder cancer	Rigshospitalet, Denmark	Recruiting	No outcome recorded
Phase 4	NCT06770530	Jun 2024 → Jun 2027 expected	urinary bladder disorder	Rigshospitalet, Denmark	Recruiting	No outcome recorded
Phase 4	NCT05176379	Feb 2022 → Dec 2024 overdue	—	University of Oklahoma	Recruiting	No outcome recorded
Phase 4	NCT04122560	Nov 2019 → Mar 2021	candidiasis, obesity disorder	Radboud University Medical Center	Completed	No outcome recorded
Phase 4	NCT02663674	Dec 2015 → Jun 2018	coccidioidomycosis	National Institute of Allergy and Infectious Diseases (NIAID)	Terminated	No outcome recorded
Phase 4	NCT01535469	Jul 2012 → Jun 2015	Cryptococcal meningitis	University of Minnesota	Completed	No outcome recorded
Phase 4	NCT00537888	Sep 2007 → Dec 2010	fungal lung infectious disease	Capital Medical University	Unknown	No outcome recorded
Phase 4	NCT02181946	May → Jul 2001	HIV infectious disease	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00001542	Jul 1996 → Nov 2001	AIDS, oral candidiasis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 4	NCT00001107	? → Nov 2005	candidiasis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 4	NCT00000951	? → May 2002	HIV infectious disease, oral candidiasis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase not applicable33 trials
—	NCT07396857	Nov 2025 → Dec 2026 expected	cardiovascular disorder	University of Sherbrooke	Recruiting	No outcome recorded
—	NCT07033962	Jun 2025 → Jun 2026 overdue	tinea unguium	Assiut University	Not yet recruiting	No outcome recorded
—	NCT05471063	Aug 2022 → Feb 2023	Cryptococcal meningitis	Peking Union Medical College Hospital	Unknown	No outcome recorded
—	NCT07557966	Jan → Dec 2022	fungal keratitis	Tanta University	Completed	No outcome recorded
—	NCT03828773	Feb 2019 → Nov 2027 expected	acute myeloid leukemia, aspergillosis, candidiasis	Bochud Pierre-Yves	Recruiting	No outcome recorded
—	NCT02624453	Jul 2015 → Mar 2018	Cryptococcal meningitis	ANRS, Emerging Infectious Diseases	Unknown	No outcome recorded
—	NCT02183779	Jun 2014 → Oct 2016	Raynaud disease	University Hospital, Grenoble	Unknown	No outcome recorded
—	NCT01096706	Jul 2011 → Jan 2012	heart disorder, vascular disorder	University of Edinburgh	Completed	No outcome recorded
—	NCT00936182	Jul 2009 → Jul 2010	autism spectrum disorder	The Center for Autism and Related Disorders	Unknown	No outcome recorded
—	NCT01447511	May 2009 → Jun 2013	—	University of Minnesota	Completed	No outcome recorded
—	NCT00023530	Sep 2001 → Aug 2006	graft versus host disease, leukemia, myelodysplastic syndrome, plasma cell myeloma	National Heart, Lung, and Blood Institute (NHLBI)	Completed	No outcome recorded
—	NCT00226538	Aug 1999 → ?	—	Hadassah Medical Organization	Completed	No outcome recorded
—	NCT00002112	—	HIV infectious disease, oral candidiasis	Pfizer	Completed	No outcome recorded
—	NCT00002010	—	HIV infectious disease, meningitis	Pfizer	Completed	No outcome recorded
—	NCT00002132	—	HIV infectious disease, esophageal candidiasis	Janssen Pharmaceuticals	Completed	No outcome recorded
—	NCT00002077	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00002306	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00002325	—	HIV infectious disease, coccidioidomycosis	Pfizer	Completed	No outcome recorded
—	NCT00002040	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00002282	—	HIV infectious disease, oral candidiasis	Pfizer	Completed	No outcome recorded
—	NCT00000627	? → Nov 1994	HIV infectious disease, histoplasmosis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002038	—	HIV infectious disease, candidiasis	Pfizer	Completed	No outcome recorded
—	NCT00002075	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00002304	—	HIV infectious disease, esophageal candidiasis	Pfizer	Completed	No outcome recorded
—	NCT00000708	? → Jul 1991	Cryptococcal meningitis, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002294	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00000639	? → Sep 1997	Cryptococcal meningitis, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002076	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00002305	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00000744	? → Dec 1995	HIV infectious disease, esophageal candidiasis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002068	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00002113	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded
—	NCT00002074	—	Cryptococcal meningitis, HIV infectious disease	Pfizer	Completed	No outcome recorded

Also used as a comparator or background therapy in 75 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT04930107 Comparator	Dec 2021 → Apr 2029 expected	vulvovaginal candidiasis	University of Manitoba	Active not recruiting	No outcome recorded
Phase 112 trials
Phase 1	NCT07341672 Comparator	Dec 2026 → Apr 2027 expected	—	Sunshine Lake Pharma Co., Ltd.	Not yet recruiting	No outcome recorded
Phase 1	NCT06847464 Background	Jan → May 2025	respiratory syncytial virus infectious disease	Enanta Pharmaceuticals, Inc	Completed	No outcome recorded
Phase 1	NCT06616168 Background	Sep 2023 → Aug 2026 overdue	bacterial vaginosis	Danylo Halytsky Lviv National Medical University	Active not recruiting	No outcome recorded
Phase 1	NCT05862714 Comparator	Mar → Sep 2022	pityriasis versicolor	Combined Military Hospital Abbottabad	Completed	No outcome recorded
Phase 1	NCT05076409 Background	Oct 2021 → Jan 2022	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT03028103 Background	Mar 2017 → Oct 2019	diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, mediastinal malignant lymphoma	Epizyme, Inc.	Completed	No outcome recorded
Phase 1	NCT02809768 Background	Apr → Aug 2016	—	Eisai Inc.	Completed	No outcome recorded
Phase 1	NCT02532192 Background	Dec 2015 → Dec 2019	lymphoma	M.D. Anderson Cancer Center	Withdrawn	No outcome recorded
Phase 1	NCT00860275 Comparator	Apr → Jun 2009	Alzheimer disease	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 1	NCT01042704 Background	Feb 2008 → Jan 2011	plasma cell myeloma	Robert Redner, MD	Completed	No outcome recorded
Phase 1	NCT01511770 Comparator	Aug 2002	—	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded
Phase 1	NCT01511757 Comparator	Jun 2002	—	Dr. Reddy's Laboratories Limited	Completed	No outcome recorded

Phase 1/22 trials
Phase 1/2	NCT04988555 Background	Feb 2022 → Jun 2027 expected	acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma	Sumitomo Pharma America, Inc.	Recruiting	No outcome recorded
Phase 1/2	NCT00509834 Background	Jul 2008 → Jan 2009	candidemia	AM-Pharma	Withdrawn	No outcome recorded
Phase 216 trials
Phase 2	NCT06859424 Background	Jul 2025 → Jun 2028 expected	B-cell chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, chronic myelomonocytic leukemia +3	Center for International Blood and Marrow Transplant Research	Recruiting	No outcome recorded
Phase 2	NCT06771063 Comparator	Jan → Jul 2025 overdue	vaginitis	Cisen Pharmaceutical CO., LTD.	Recruiting	No outcome recorded
Phase 2	NCT05059145 Comparator	Apr 2022 → Dec 2024	vulvovaginal candidiasis	Karolinska Institutet	Unknown	No outcome recorded
Phase 2	NCT03112031 Background	Oct 2017 → Jul 2018	HIV infectious disease, meningoencephalitis, streptococcal meningitis	Oxford University Clinical Research Unit, Vietnam	Completed	No outcome recorded
Phase 2	NCT03253094 Comparator	Aug 2017 → May 2018	vulvovaginal candidiasis	Scynexis, Inc.	Completed	No outcome recorded
Phase 2	NCT02971007 Comparator	Nov 2016 → May 2017	vulvovaginal candidiasis	Matinas BioPharma Nanotechnologies, Inc.	Completed	No outcome recorded
Phase 2	NCT02734862 Comparator	Jul 2016 → Jun 2019	candidemia	Cidara Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT02733432 Comparator	Jun → Nov 2016	vulvovaginal candidiasis	Cidara Therapeutics Inc.	Completed	No outcome recorded
Phase 2	NCT02679456 Comparator	Nov 2015 → Aug 2016	vulvovaginal candidiasis	Scynexis, Inc.	Completed	No outcome recorded
Phase 2	NCT02244606 Comparator	Sep 2014 → Jun 2016	candidemia	Scynexis, Inc.	Completed	No outcome recorded
Phase 2	NCT03159845 Background	Jan 2014 → Sep 2019	disease related to hematopoietic stem cell transplant	Azienda Ospedaliero, Universitaria Pisana	Completed	No outcome recorded
Phase 2	NCT01562132 Comparator	Sep 2013 → Jul 2014	cryptococcosis	Yale University	Terminated	No outcome recorded
Phase 2	NCT01891331 Comparator	Aug 2013 → Dec 2014	vulvovaginal candidiasis	Viamet	Completed	No outcome recorded
Phase 2	NCT01501708 Background	Dec 2011 → Jun 2017	disease related to hematopoietic stem cell transplant, leukemia	Shanghai Jiao Tong University School of Medicine	Unknown	No outcome recorded
Phase 2	NCT00012467 Background	Jan 2000 → Jul 2001	Cryptococcal meningitis, HIV infectious disease	InterMune	Completed	No outcome recorded
Phase 2	NCT00000776 Background	? → Sep 1996	Cryptococcal meningitis, HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT06666322 Comparator	May 2025 → Apr 2032 expected	Cryptococcal meningitis, HIV infectious disease	University of Minnesota	Recruiting	No outcome recorded
Phase 2/3	NCT04734405 Comparator	Oct 2019 → Nov 2022	vulvovaginal candidiasis	ProFem GmbH	Unknown	No outcome recorded
Phase 2/3	NCT03945448 Comparator	Jun 2019 → Jun 2027 expected	Cryptococcal meningitis	Makerere University	Recruiting	No outcome recorded
Phase 325 trials
Phase 3	NCT06774144 Comparator	Oct 2025 → Dec 2028 expected	fungal infectious disease	Fernanda P Silveira, MD, MS	Enrolling by invitation	No outcome recorded
Phase 3	NCT06055257 Background	Jan 2025 → Dec 2027 expected	osteoradionecrosis of the mandible	Sunnybrook Health Sciences Centre	Recruiting	No outcome recorded
Phase 3	NCT05421858 Comparator	Dec 2024 → Jan 2028 expected	candidemia	Basilea Pharmaceutica	Recruiting	No outcome recorded
Phase 3	NCT07311759 Comparator	Aug 2024 → Dec 2025 overdue	paronychia	Cairo University	Active not recruiting	No outcome recorded
Phase 3	NCT05367089 Comparator	Aug 2022 → Apr 2026 overdue	vulvovaginal candidiasis	Maastricht University Medical Center	Recruiting	No outcome recorded
Phase 3	NCT05178862 Comparator	Aug 2022 → Nov 2025	candidemia	Scynexis, Inc.	Terminated	No outcome recorded
Phase 3	NCT05074602 Comparator	Sep 2021 → Sep 2023	vulvovaginal candidiasis	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT04956419 Comparator	Apr → Sep 2021	vulvovaginal candidiasis	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT04368559 Comparator	May 2020 → Jan 2026	aspergillosis, candidemia, pneumocystosis	Mundipharma Research Limited	Completed	No outcome recorded
Phase 3	NCT04029116 Background	Oct 2019 → Sep 2021	vulvovaginal candidiasis	Scynexis, Inc.	Completed	No outcome recorded
Phase 3	NCT03840616 Comparator	Mar 2019 → Dec 2020	vulvovaginal candidiasis	Mycovia Pharmaceuticals Inc.	Completed	No outcome recorded
Phase 3	NCT03667690 Comparator	Oct 2018 → Oct 2021	candidemia	Cidara Therapeutics Inc.	Completed	No outcome recorded
Phase 3	NCT03002012 Background	Nov 2017 → Mar 2018	cryptococcosis	University of Minnesota	Terminated	No outcome recorded
Phase 3	NCT01503515 Comparator	Mar 2013 → Dec 2019	fungal infectious disease, hematopoietic and lymphoid cell neoplasm	Children's Oncology Group	Completed	No outcome recorded
Phase 3	NCT01974375 Comparator	Aug 2012 → Jun 2014	—	Asan Medical Center	Unknown	No outcome recorded
Phase 3	NCT01307579 Comparator	Apr 2011 → Jun 2018	acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation, acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent, acute myeloid leukemia with minimal differentiation +9	Children's Oncology Group	Completed	No outcome recorded
Phase 3	NCT01176058 Comparator	Dec 2010 → Nov 2011	candidemia	Pfizer	Terminated	No outcome recorded
Phase 3	NCT01058174 Comparator	Dec 2009 → May 2012	fungal infectious disease	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00761267 Background	Feb 2009 → Feb 2018	candidemia	Pfizer	Completed	No outcome recorded
Phase 3	NCT00811928 Comparator	Nov 2008 → May 2010	leukopenia	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00689338 Background	Jul 2008 → May 2010	candidiasis, invasive	Pfizer	Completed	No outcome recorded
Phase 3	NCT00423267 Comparator	May 2007 → May 2009	coccidioidomycosis	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00189709 Comparator	Aug 2004 → Jul 2006	candidemia	Astellas Pharma Inc	Completed	No outcome recorded
Phase 3	NCT00075803 Comparator	Nov 2003 → Sep 2006	infectious disease, leukemia, lymphoma	Medical College of Wisconsin	Completed	No outcome recorded
Phase 3	NCT00666185 Comparator	Aug 2003 → Feb 2004	oral candidiasis	Astellas Pharma Inc	Completed	No outcome recorded

Phase 410 trials
Phase 4	NCT07342153 Comparator	Nov 2025 → Feb 2026 overdue	tinea corporis	Urooj Fatima	Recruiting	No outcome recorded
Phase 4	NCT04626258 Comparator	Mar 2021 → Mar 2024	vulvovaginal candidiasis	Maastricht University Medical Center	Unknown	No outcome recorded
Phase 4	NCT02180828 Comparator	Jul 2014 → Sep 2015	vulvovaginal candidiasis	Peking University Shenzhen Hospital	Completed	No outcome recorded
Phase 4	NCT02079298 Comparator	Apr 2014 → Sep 2015	infectious disease, patent ductus arteriosus	Karolinska Institutet	Completed	No outcome recorded
Phase 4	NCT02180100 Comparator	Aug 2013 → Jun 2014	vulvovaginal candidiasis	Peking University Shenzhen Hospital	Completed	No outcome recorded
Phase 4	NCT00841971 Comparator	Feb 2010 → Jul 2013	fungal lung infectious disease	University of Pittsburgh	Completed	No outcome recorded
Phase 4	NCT00634166 Background	Sep 2007 → Dec 2013	—	Mylan Inc.	Terminated	No outcome recorded
Phase 4	NCT00496197 Background	Jul 2007 → Jun 2010	candidiasis	Pfizer	Completed	No outcome recorded
Phase 4	NCT00553137 Comparator	Nov 2006 → Dec 2007	oral candidiasis	Netherlands Organisation for Scientific Research	Completed	No outcome recorded
Phase 4	NCT00304772 Comparator	Aug 2006 → Dec 2008	candidiasis, infectious disease with sepsis	Kyoto University	Withdrawn	No outcome recorded

Phase not applicable6 trials
—	NCT05434104 Comparator	Apr 2026 → Dec 2027 expected	bacterial vaginosis, vulvovaginal candidiasis	Guy's and St Thomas' NHS Foundation Trust	Recruiting	No outcome recorded
—	NCT05895162 Background	Jun 2023 → Dec 2024	vulvovaginal candidiasis	FEMPHARMA Kft.	Unknown	No outcome recorded
—	NCT05795491 Comparator	Apr → May 2023	vulvovaginal candidiasis	Cairo University	Completed	No outcome recorded
—	NCT03939273 Comparator	Mar 2022 → Mar 2023	autoinflammatory syndrome, coronary artery disorder	Radboud University Medical Center	Unknown	No outcome recorded
—	NCT01290198 Comparator	Feb 2011 → Apr 2012	—	University Hospital, Grenoble	Completed	No outcome recorded
—	NCT00830856 Background	Oct 2006 → Oct 2008	Cryptococcal meningitis, HIV infectious disease	University of Zimbabwe	Completed	No outcome recorded

Press releases naming this drug 2 releases

Date	Issuer	Release
2005-01-14	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval Of Fluconazole Injection tevapharm.com ↗
2004-07-29	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval Of Fluconazole Tablets And Injection tevapharm.com ↗

Evidence & citations 23 cited values

Every value below carries the sentence it was read from. 217 sources stand behind the page.

Field	Value	Cited text
Known as	Fluconazole	“'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin;...” NCT00634166 ↗ 212 “All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at...” NCT01501708 ↗ “A Randomized, Open Label, Comparative Multicenter Study Of Voriconazole Versus Conventional Amphotericin B Followed By Fluconazole In The Treatment Of Candidaemia In Non...” NCT00163111 ↗ “For all patients without documented proven or probable invasive fungal disease (IFD), patients will receive fluconazole during the treatment in the laminar air flow units (LAF).” NCT04273178 ↗ “3. Fluconazole 1200mg/day for 14 days Consolidation Therapy: Fluconazole 800mg/day from 2 to 10 weeks Secondary Prophylaxis: Fluconazole 200mg/day through 1 year minimum” NCT06666322 ↗ “Fluconazole will be administered every day for 8 consecutive days with a single dose of NX-5948/placebo coadministered on Day 4” NCT06593457 ↗ “Control women with candida will be given a fluconazole 150mg capsule to take orally the same day.” NCT05434104 ↗ “hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days)” NCT00509834 ↗ “Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole” NCT02366884 ↗ “Fluconazole is used for recipients with risk factors for yeast infections” NCT06774144 ↗ “Arm (2) will receive Fluconazole (300mg once weekly for 3monthes).” NCT03171584 ↗ “the recommended maximum dose of fluconazole daily is 200 mg.” NCT06859424 ↗ “Posaconazole, Voriconazole, or Fluconazole” NCT04988555 ↗ “50 mg Fluconazole daily (morning)” NCT06055257 ↗ “fluconazole” NCT05795491 ↗ NCT02733432 ↗ NCT02325011 ↗ NCT01511770 ↗ NCT06173596 ↗ NCT00423267 ↗ NCT04502277 ↗ NCT07396857 ↗ NCT00000776 ↗ NCT02093728 ↗ NCT03634345 ↗ NCT00002339 ↗ NCT01524081 ↗ NCT01511757 ↗ NCT00002077 ↗ NCT05176379 ↗ NCT05140096 ↗ NCT02730442 ↗ NCT01806623 ↗ NCT04495608 ↗ NCT00056368 ↗ NCT00797420 ↗ NCT05895162 ↗ NCT02532192 ↗ NCT02181946 ↗ NCT00002075 ↗ NCT05074602 ↗ NCT05471063 ↗ NCT00226538 ↗ NCT05657613 ↗ NCT00553137 ↗ NCT00189709 ↗ NCT04193319 ↗ NCT04122560 ↗ NCT02679456 ↗ NCT02111629 ↗ NCT00002074 ↗ NCT05367089 ↗ NCT00496197 ↗ NCT04038008 ↗ NCT03135106 ↗ NCT07565441 ↗ NCT07395024 ↗ NCT07342153 ↗ NCT07295314 ↗ NCT00000788 ↗ NCT06709196 ↗ NCT03028103 ↗ NCT02079298 ↗ NCT02180100 ↗ NCT00004938 ↗ NCT02145832 ↗ NCT07557966 ↗ NCT04933682 ↗ NCT02663674 ↗ NCT00935363 ↗ NCT02941068 ↗ NCT02222922 ↗ NCT07341672 ↗ NCT00353561 ↗ NCT02971007 ↗ NCT06771063 ↗ NCT00761267 ↗ NCT06345794 ↗ NCT00012467 ↗ NCT03476317 ↗ NCT06770530 ↗ NCT04930107 ↗ NCT02809768 ↗ NCT00002122 ↗ NCT00811928 ↗ NCT00002304 ↗ NCT04850651 ↗ NCT01974375 ↗ NCT00666185 ↗ NCT05661591 ↗ NCT07439250 ↗ NCT00860275 ↗ NCT00841971 ↗ NCT01169402 ↗ NCT02244606 ↗ NCT00002068 ↗ NCT00689338 ↗ NCT00002282 ↗ NCT00002277 ↗ NCT05421858 ↗ NCT00000676 ↗ NCT03610945 ↗ NCT00166166 ↗ NCT00734539 ↗ NCT04368559 ↗ NCT05147727 ↗ NCT05602597 ↗ NCT03451110 ↗ NCT02275975 ↗ NCT03828773 ↗ NCT00830856 ↗ NCT04029116 ↗ NCT00002305 ↗ NCT03036046 ↗ NCT03942029 ↗ NCT00911235 ↗ NCT00645242 ↗ NCT06616168 ↗ NCT01026714 ↗ NCT00304772 ↗ NCT00002076 ↗ NCT00000627 ↗ NCT00170430 ↗ NCT01683760 ↗ NCT01891331 ↗ NCT00003883 ↗ NCT02765256 ↗ NCT00002533 ↗ NCT03667690 ↗ NCT01562132 ↗ NCT02195466 ↗ NCT00002132 ↗ NCT00503542 ↗ NCT06274554 ↗ NCT03840616 ↗ NCT01176058 ↗ NCT03253094 ↗ NCT03112031 ↗ NCT05178862 ↗ NCT02093390 ↗ NCT01503515 ↗ NCT00002112 ↗ NCT04956419 ↗ NCT01447511 ↗ NCT01772290 ↗ NCT00002040 ↗ NCT02624453 ↗ NCT00313131 ↗ NCT00002038 ↗ NCT01290198 ↗ NCT00000951 ↗ NCT03945448 ↗ NCT00002399 ↗ NCT02180828 ↗ NCT00002113 ↗ NCT01950507 ↗ NCT00145249 ↗ NCT00936182 ↗ NCT01354314 ↗ NCT05059145 ↗ NCT00964106 ↗ NCT05862714 ↗ NCT04702464 ↗ NCT00001542 ↗ NCT02997059 ↗ NCT05478772 ↗ NCT01953744 ↗ NCT00002294 ↗ NCT00000639 ↗ NCT02734862 ↗ NCT00000708 ↗ NCT06922344 ↗ NCT01058174 ↗ NCT00000744 ↗ NCT04201054 ↗ NCT00001107 ↗ NCT00075803 ↗ NCT04551963 ↗ NCT04464577 ↗ NCT01096706 ↗ NCT06822166 ↗ NCT00537888 ↗ NCT00002010 ↗ NCT01307579 ↗ NCT01535469 ↗ NCT06847464 ↗ NCT01386593 ↗ NCT02183779 ↗ NCT01153724 ↗ NCT01715922 ↗ NCT03002012 ↗ NCT00004808 ↗ NCT00002325 ↗ NCT01825031 ↗ NCT07311759 ↗ NCT00001017 ↗ NCT01924299 ↗ NCT03159845 ↗ NCT00002446 ↗ NCT05848492 ↗ NCT07636018 ↗ NCT00023530 ↗ NCT00885703 ↗ NCT00001937 ↗ NCT04871724 ↗ NCT00000826 ↗ NCT00002306 ↗ NCT03939273 ↗ NCT05076409 ↗ NCT04626258 ↗ NCT07033962 ↗ NCT04734405 ↗ NCT02122770 ↗
Known as	[3H]-Fluconazole	ChEMBL registry synonym — accepted as the source's own label CHEMBL106 ↗
Known as	Alkanazole	ChEMBL registry synonym — accepted as the source's own label CHEMBL106 ↗
Known as	BAYT-006267	ChEMBL registry synonym — accepted as the source's own label CHEMBL106 ↗
Known as	Canesten oral	ChEMBL registry synonym — accepted as the source's own label CHEMBL106 ↗
Known as	Diflucan	“The Objective of This Study Was an Open-label, Randomized, 2-way Crossover to Compare the Single-dose Relative Bioavailability of Flucanazole 40mgm/ml 35 ml Suspension and...” NCT04502277 ↗ 4 “Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.” NCT04038008 ↗ “In case of history of zoster or fungal infection a prophylaxis with Acyclovir or Diflucan should be also considered.” NCT01042704 ↗ “Drug: Diflucan (fluconazole)” NCT00496197 ↗ “Fluconazole Diflucan” NCT02971007 ↗
Known as	Diflucan one	ChEMBL registry synonym — accepted as the source's own label CHEMBL106 ↗
Known as	Difluconazole	ChEMBL registry synonym — accepted as the source's own label CHEMBL106 ↗
Known as	FCZ	“To compare the safety and effectiveness of fluconazole (FCZ) and amphotericin B (AMB), alone or in combination with flucytosine (FLC), as treatment for acute cryptococcal meningitis” NCT00000708 ↗ 2 “The objectives were to assess the influence of antifungal treatment with Fluconazole (FCZ) on the rate of ASCA and endoscopic recurrence at 6 months.” NCT02997059 ↗ “Fluconazole (FCZ)” NCT02195466 ↗
Known as	Fluconazol	ChEMBL registry synonym — accepted as the source's own label CHEMBL106 ↗
Known as	Fluconazol 200ml (fluconazolum 400mg; Baxter; Czech Republic)	“Fluconazol 200ml (fluconazolum 400mg; Baxter; Czech Republic)” NCT01524081 ↗
Known as	Fluconazole Kabi	“Fluconazole Kabi, Fresenius 2mg/ml Fluconazole will be administered at a loading dose of 25 mg/kg on the first day and followed by a maintenance dose of 12 mg/kg or 20 mg/kg...” NCT02145832 ↗
Known as	Fluconazoli	ChEMBL registry synonym — accepted as the source's own label CHEMBL106 ↗
Known as	FLZ	“The overall aim of this study is to investigate if vaginally applied 1% chlorhexidine gluconate (CHG) could be an alternative treatment to oral fluconazole (FLZ), both during...” NCT05059145 ↗ 1 “Participants ingested fluconazole (150 mg; FLZ, CYP450 inhibitor) or placebo (PLC, microcrystalline cellulose)” PMID 41420405 ↗ Dec 2025
Known as	NSC-758661	ChEMBL registry synonym — accepted as the source's own label CHEMBL106 ↗
Known as	Triflucan	ChEMBL registry synonym — accepted as the source's own label CHEMBL106 ↗
Known as	UK-49,858	“Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable...” NCT00002306 ↗ 4 “Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired...” NCT00002074 ↗ “Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome” NCT00002294 ↗ “Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome” NCT00001017 ↗ “A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis” NCT00002068 ↗
Known as	Zoltec	ChEMBL registry synonym — accepted as the source's own label CHEMBL106 ↗
Action	Inhibit	“fluconazole was used to inhibit cytochrome P450 2C9-mediated epoxyeicosatrienoic acid synthesis” PMID 21555712 ↗ May 2011
Modality	Small molecule	“Fluconazole is a triazole antifungal agent” NCT00000627 ↗
Route	Intravenous	“Patients who are unable to take the drug orally may receive it intravenously until oral administration is possible.” NCT00000627 ↗
Route	Oral	“Patients who are unable to take the drug orally may receive it intravenously until oral administration is possible.” NCT00000627 ↗
Target	CYP2C9	“fluconazole was used to inhibit cytochrome P450 2C9-mediated epoxyeicosatrienoic acid synthesis” PMID 21555712 ↗ May 2011